Fig. 4: Effect of variations in FHR-4 plasma and ocular levels on disease progression in AMD driven by rs1061170 risk.
a Patients with a Risk/Risk diplotype and no risk alleles at the Chr10 AMD locus were selected based on genotype at rs61818956 (TT, FHR-4↑ group) and rs10494745 (AA, FHR-4↓ group), with the reference group labeled FHR-4↔ (CC at rs61818956, GG at rs10494745). b Table showing the number and frequency of conversions recorded in each eye that met the inclusion criteria. Differences between groups were assessed using a chi-squared test. P-values are two-sided. c Box plots showing the median age of first recorded conversion to late AMD (cRORA or neovascular AMD) and conversion curves for earliest conversion generated using Cox proportional hazard regression models adjusted for age and AMD severity at first visit (81 patients, see a). In the box plot, the horizontal center lines correspond to the medians and the boxes delineate the 25th/75th percentile. The vertical solid lines represent the full range of the age distribution in each group. Dots beyond this line indicate potential outliers. Association with age at first conversion was assessed using the Kruskal–Wallis test. Associations with time to conversion were determined using the log-rank test. All p-values are two-sided. d Hazard ratios and 95% confidence interval (CI) generated using mixed-effect Cox proportional hazard regression models adjusted for age and AMD severity at first visit and including a frailty term to account for correlations between eyes from the same patient (131 eyes from 81 patients, see a). All p-values are two-sided.
